Landmark Report Published on the Status of Inclusion, Diversity, Equity and Accessibility (IDEA) in Canada’s Life Sciences Sector
Pacylex Pharmaceuticals Announces First Patient Dosed in a Phase 2a Study of PCLX-001 in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
RYALTRIS®, a new combination prescription nasal spray for moderate to severe seasonal allergic rhinitis (SAR), now available across Canada